

Support for new claims 83 through 100 can be found in the claims as previously pending and throughout the specification. Specifically, support for new claims 83-90 may be found at least at page 5, line 15 through page 13, line 18, and in the Sequence Listing. Support for new claims 91-100 may be found at least at page 5, line 15 through page 13, line 18, and at page 38, lines 3-4. Support for new claims 99 and 100 may be found at least at page 17, line 5 through page 18, line 22.

The specification has been amended to correct a typographical error. Support for the recitation of "0.5%" SDS in the specification may be found at least in Sambrook *et al.* Molecular Cloning: A Laboratory Manual, 2<sup>nd</sup> Edition, Cold Spring Harbor Laboratory Press (1989), sections 9.47-9.62, incorporated by reference at page 14, lines 9-10 and page 36, lines 34-35 of the specification. The specification has further been amended to include a substitute abstract. The abstract is identical to the originally filed abstract, and is submitted herewith on a separate page (Page 107).

No new matter has been added by these amendments.

Amendment of the claims should in no way be construed as an acquiescence to any of the Examiner's rejections and was done solely to expedite prosecution. Applicants reserve the right to pursue the claims as originally filed in this or a separate application(s).

**Rejection of Claims 78-82 Under 35 U.S.C. 112, first paragraph**

Claims 78-82 are rejected under 35 U.S.C. 112, first paragraph, as lacking enablement for any alternative splice forms of a transcript of a B7-1 or B7-2 T cell costimulatory gene. Applicants respectfully disagree; however, in the interests of expediting prosecution, claims 78-82 have been canceled. Therefore, this rejection is rendered moot.

Applicants respectfully submit that the instant rejection does not apply to new claims 83-100. Claims 83-100 are drawn to isolated nucleic acid molecules consisting of the nucleotide sequences of SEQ ID NOs: 1, 4, 6, 7, 8, 10, 12, 14, 62, and 64 or of nucleotide sequences which hybridize to the complements of these SEQ ID NOs under

stringent conditions which are defined in the claims. Claims 93-100 are fully enabled by the specification and the Sequence Listing.

**Rejection of Claims 78-82 Under 35 U.S.C. 102(e)**

Claims 78-82 are rejected under 35 U.S.C. 102(e) as being anticipated by Freeman *et al.* (U.S. Patent No. 5,942,607). Applicants respectfully disagree. However, solely in the interests of expediting prosecution, claims 78-82 have been canceled. Therefore, this rejection is rendered moot.

**CONCLUSION**

In view of the foregoing remarks, Applicants believe newly added claims 83-100 are enabled, distinctly claimed, and inventive. Accordingly, allowance is requested.

If a telephone conversation with Applicants' attorney would help expedite the prosecution of the above-identified application, the Examiner is urged to call Applicants' attorney at (617) 227-7400.

Respectfully submitted,



DeAnn F. Smith  
Registration No. 36,683  
Attorney for Applicants

LAHIVE & COCKFIELD, LLP  
28 State Street  
Boston, MA 02109  
Tel. (617) 227-7400

Dated: April 11, 2000